What Avanzanite Bioscience does

Avanzanite Bioscience B.V. is a privately-held, Amsterdam-based specialty pharmaceutical company founded in 2022 that operates a pan-European commercialization platform for orphan medicines across 32 countries in the European Economic Area, the United Kingdom, and Switzerland. The company holds a Wholesale Distributor Authorization (WDA) license (no. 109223 G) issued by the Dutch Competent Authorities, enabling it to act as a fully authorized distributor of medicinal products within Europe. Avanzanite partners with emerging and mid-sized biopharmaceutical originators through exclusive licensing and distribution agreements, offering end-to-end commercialization capabilities including regulatory navigation, market access, pricing and reimbursement, medical affairs, and distribution—services that the target biotech firms would otherwise have to build independently at significant cost.

The company's commercialized portfolio comprises three products secured through three strategic alliances established in three years: PYRUKYND® (mitapivat) under an exclusive 2025 agreement with Agios Pharmaceuticals for the European Economic Area, UK, and Switzerland; SIBNAYAL® under an exclusive 2023 distribution agreement with Advicenne across Germany, Austria, Switzerland, Liechtenstein, Greece, Ireland, Cyprus, and Malta; and AKANTIOR® under an exclusive 2022 license and supply agreement with SIFI S.p.A. across 26 EEA countries and Switzerland. As of May 2026, Avanzanite has led four rare disease product launches in Europe, including the May 2026 European Commission approval of PYRUKYND for thalassemia. Revenue is generated through product sales, milestone payments, and royalties under these licensing/distribution arrangements.

Avanzanite's go-to-market is an enterprise field sales model targeting biotech originators, supported by a 'Champions League' team of more than 90 rare disease pharma professionals as of March 2026, growing to over 100 by May 2026. The company has established dedicated country leadership in priority markets including France (General Manager Constance Sabbagh, March 2026) and Spain (Country Manager María Baquerizo López-Quectuy, June 2026). In November 2025, Avanzanite closed its first institutional funding round—a €32 million Series A led by MVM Partners—to scale infrastructure across all 32 European countries, support ongoing product launches, and pursue further alliances and acquisitions.

Name

Avanzanite Bioscience

Legal name

Avanzanite Bioscience B.V.

Website

https://avanzanite.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

Avanzanite Bioscience is a pan-European specialty pharmaceutical company that commercializes and distributes orphan medicines across 32 European countries on behalf of biotech originators through exclusive licensing and distribution agreements. Founded in 2022 and headquartered in Amsterdam, it offers end-to-end market access, pricing, regulatory, medical affairs, and distribution services for rare disease therapies.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals / Orphan Drug Commercialization

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Orphan drug commercialization
• Rare disease medicines
• Specialty pharmaceutical distribution
• Pan-European market access
• Licensing partnerships

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Others

Revenue model

1. Licensing and Distribution Partnerships: Avanzanite earns revenue through exclusive licensing and distribution agreements with biotech/pharma originators for commercialization of orphan medicines across Europe. Revenue is generated via product sales, milestone payments, and potentially royalties from commercialized rare disease therapies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Avanzanite offers end-to-end commercialization and distribution partnerships to research-based biopharmaceutical originators, licensing their approved or late-stage orphan medicines and bringing them to patients across 32 European countries. The company handles regulatory navigation, pricing and reimbursement, market access, medical affairs, and physical distribution, enabling biotech innovators to unlock European value of their rare disease therapies without building local infrastructure. Three products are currently commercialized under this model: PYRUKYND, Sibnayal, and AKANTIOR.

Product overview

Avanzanite Bioscience operates as a pan-European specialty pharmaceutical company offering end-to-end commercialization and distribution partnerships for rare disease medicines. The company provides a unified platform spanning 32 European countries through three commercialized products: PYRUKYND® (mitapivat) for pyruvate kinase deficiency and thalassaemia, Sibnayal® for distal Renal Tubular Acidosis, and AKANTIOR® for Acanthamoeba Keratitis. These products are secured through exclusive licensing and distribution agreements with partner pharmaceutical companies (Agios Pharmaceuticals, Advicenne, and SIFI respectively), enabling biotech innovators to unlock the full European commercial potential of their orphan medicines without building local infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

• PYRUKYND: Oral pyruvate kinase activator for treatment of PK deficiency and thalassaemia, commercialized by Avanzanite across Europe under partnership with Agios Pharmaceuticals.
• SIBNAYAL
• AKANTIOR

Products and services

• PYRUKYND (mitapivat) An oral pyruvate kinase (PK) activator approved by the European Commission in 2022 for adults with Pyruvate Kinase (PK) Deficiency and in 2026 for anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia. Commercialized by Avanzanite under exclusive agreement with Agios Pharmaceuticals across the EEA, UK, and Switzerland for healthcare providers treating these rare hematological conditions.
• Sibnayal A medicinal product approved by the European Commission in 2021 for the treatment of distal Renal Tubular Acidosis (dRTA), a rare kidney disease. Distributed by Avanzanite under an exclusive distribution agreement with Advicenne across Germany, Austria, Switzerland, Liechtenstein, Greece, Ireland, Cyprus, and Malta for patients with this rare renal condition.
• AKANTIOR A medicinal product approved by the European Commission in 2024 for the treatment of Acanthamoeba Keratitis, a rare and severe ophthalmologic parasitic infection that accounts for 50% of blindness among contact lens users. Commercialized by Avanzanite under exclusive license and supply agreement with SIFI across 26 countries within the European Economic Area and Switzerland for affected patients and their treating ophthalmologists.
• Pan-European Orphan Drug Commercialization Partnership End-to-end commercialization and distribution partnership service for emerging or early-stage biopharmaceutical originators with approved or late-stage orphan medicines. The service covers regulatory navigation, pricing and reimbursement negotiations, market access, medical affairs, and WDA-licensed physical distribution across 32 European countries (EEA, UK, Switzerland) under bespoke exclusive licensing or distribution agreements. Targeted at biotech originators that lack European infrastructure or face regulatory and market access complexity.

Quantifiable outcome

• Revenue tripled year-over-year in Q3 2025 and climbed over 20% quarter-on-quarter
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered flagship, minor and core.

• Agios PharmaceuticalsflagshipStrategic or Co-development Partner · 1 June 2025Avanzanite entered an exclusive agreement with Agios Pharmaceuticals in June 2025 to commercialize and distribute PYRUKYND (mitapivat) across the European Economic Area, UK, and Switzerland. PYRUKYND is a first-in-class oral pyruvate kinase activator approved for adults with PK deficiency and later for thalassemia. The partnership includes rights for potential future indications and represents Avanzanite's flagship rare disease launch.
• NewBridge PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 1 January 2025Agios Pharmaceuticals established a revenue-sharing partnership with NewBridge Pharmaceuticals for the GCC region to commercialize PYRUKYND ex-U.S., pending regulatory approvals in those markets. Avanzanite is the equivalent partner for the European market.
• AdvicennecoreChannel Partner/ Reseller/ Distributor · 1 February 2023Avanzanite signed an exclusive distribution agreement with Paris-based Advicenne for Sibnayal (ADV 7103), a medicinal product approved by the European Commission for the treatment of distal Renal Tubular Acidosis (dRTA). Avanzanite distributes Sibnayal in Germany, Austria, Switzerland, Greece, Ireland, Cyprus, and Malta, with first anticipated commercial launch in Germany in mid-2023.
• SIFI S.p.A.coreStrategic or Co-development Partner · 1 January 2022Avanzanite holds exclusive license and supply agreement with SIFI for AKANTIOR (Acanthamoeba Keratitis treatment) across 26 countries within the EEA and Switzerland. SIFI partnered with Avanzanite to commercialize and distribute its investigational ultra-orphan medicine for the treatment of AK, a devastating eye infection that accounts for 50% of blindness among contact lens users.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Alexion / AstraZeneca Rare Disease: Alexion, operating as AstraZeneca's Rare Disease unit, is a global leader in commercializing rare disease therapeutics with established European infrastructure. Highly comparable therapeutic and commercial focus but at vastly larger scale and within a broader pharma portfolio.
• BioMarin Pharmaceutical: BioMarin is a global biotechnology company focused exclusively on rare diseases with significant European commercial presence. Comparable orphan drug focus but with proprietary pipeline rather than in-licensed assets.
• Chiesi Farmaceutici: Chiesi is a privately-held European-headquartered pharmaceutical company with a strong rare disease franchise (Chiesi Global Rare Diseases). Comparable focus on commercializing orphan drugs across European markets with established country-level infrastructure.

Emerging players

• Ultragenyx Pharmaceutical: Ultragenyx is a mid-stage rare disease biotech commercializing multiple orphan therapies in Europe and globally. Comparable focus on ultra-rare diseases and European commercialization, though Ultragenyx owns its pipeline.
• Orphalan: Orphalan is a European specialty pharmaceutical company focused exclusively on rare diseases, developing and commercializing orphan drugs across multiple European markets. Comparable focus on rare disease commercialization in Europe.
• Theramex: Theramex is a global specialty pharmaceutical company focused on women's health and rare conditions across Europe with established country-level infrastructure. Comparable European rare disease commercialization focus within a narrower therapeutic scope.

Direct peers

• Swedish Orphan Biovitrum (Sobi): Sobi is a Swedish-headquartered global biopharmaceutical company specializing in rare diseases across haematology, immunology and specialty care with deep pan-European commercialization infrastructure. Highly comparable to Avanzanite's orphan drug commercialization focus and European footprint.
• Recordati Rare Diseases: Recordati Rare Diseases is a global pharmaceutical group with a dedicated rare disease business that acquires, licenses and distributes orphan drugs across Europe and the US. Comparable business model of in-licensing and commercializing rare disease products across multiple geographies.
• Inceptua Group: Inceptua is a specialty pharmaceutical company providing commercialization, distribution and early access services for rare disease and specialty products across Europe. Comparable business model of helping biotech originators access European markets without building own infrastructure.
• Tanner Pharma Group: Tanner Pharma provides specialty distribution, commercialization and managed access services for rare disease products globally. Comparable outsourced commercialization model targeting emerging biopharmaceutical companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=TgKgfuPvbjQ
• LinkedInlinkedin.com/company/avanzanite

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avanzanite Bioscience